Glitaray MP 2mg/500mg/15mg Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 2mg, Metformin 500mg, and Pioglitazone 15mg, indicated for the management of type 2 diabetes mellitus. This formulation harnesses the complementary mechanisms of action of its components to achieve optimal glycemic control. Glimepiride, a sulfonylurea, stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to enhanced glucose uptake and utilization. Pioglitazone, a thiazolidinedione, acts as an insulin sensitizer by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), which modulates the transcription of insulin-responsive genes involved in glucose and lipid metabolism. The combined effect of these agents addresses multiple pathophysiological defects in type 2 diabetes, including insulin resistance and impaired insulin secretion. Glitaray MP is recommended as an adjunct to diet and exercise to improve glycemic control in patients inadequately controlled on monotherapy or dual therapy. Caution is advised in patients with hepatic or renal impairment, heart failure, or a history of lactic acidosis. Regular monitoring of blood glucose, renal function, and liver enzymes is essential during therapy.